Sponsored
Biotech capital in 2026 has already demonstrated interest at the intersection of immunology and cardiology.
Eli Lilly’s $1.2 billion acquisition of Ventyx Biosciences, Novartis’ $1.4B acquisition of Tourmaline Bio, and Monte Rosa Therapeutics’ $300 million raise highlight growing interest in therapies targeting the inflammatory drivers of cardiovascular disease. The focus is shifting beyond cholesterol management toward targeting the inflammatory pathways that contribute directly to cardiac damage and long-term disease progression.
From Concept to Clinical Execution
Therapy targeting inflammatory mechanisms in cardiology has moved from theory to strategic priority.
Lilly’s and Novartis’ deals centered on acquiring therapeutics targeting the NLRP3 inflammasome or the mediators responsible for driving inflammation in cardiovascular disease. Rather than build internally, they chose to acquire assets targeting validated inflammatory pathways, reinforcing the value placed on credible platforms in cardiovascular indications.
A Later Stage Program: Cardiol Therapeutics
While many companies in this space remain at developmental earlier stages, Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL) is operating at the late clinical stage.
Pivotal Phase 3 Execution
Cardiol’s lead candidate, CardiolRx™, is currently being evaluated in the MAVERIC Phase 3 trial for recurrent pericarditis. The drug received U.S. FDA Orphan Drug Designation grant for pericarditis in 2024.
Enrollment has surpassed 50%, with full enrollment targeted for Q2 2026. Pending positive results, this establishes a defined regulatory timeline. The trial design focuses on patients at high risk of recurrence, which may allow for efficient demonstration of treatment effect.
Structural Heart Validation
In the 109 patient Phase 2 ARCHER trial in acute myocarditis, CardiolRx™ demonstrated a statistically significant reduction in left ventricular mass over 12 weeks.
Reduction in LV mass is associated with improvements in both cardiac remodeling and clinical outcomes in heart failure. These results provide controlled clinical proof of concept that targeting inflammation may improve structural heart outcomes. There are currently no FDA approved therapies for acute myocarditis.
Strategic Expansion into Heart Failure
Cardiol is advancing CRD-38, a subcutaneous formulation intended for heart failure. Preclinical studies have shown effects on inflammation and cardiac function, and the company is completing IND-enabling studies to support a planned first in human trial.
The ARCHER structural findings strengthen the scientific rationale for expansion into this larger indication.
Capital Position
Cardiol has strengthened its balance sheet over the past six months– management has stated that current capital funds the company through full enrollment and data readout of the MAVERIC Phase 3 trial, while advancing CRD-38 through Phase 1, with runway expected into Q3 2027.
The company has also received a U.S. patent allowance covering CardiolRx™ and CRD-38 for a broad range of cardiac disorders, extending protection into 2040.
Execution Window
Some companies are raising capital on early-stage platform data. Others, such as Cardiol, are advancing late-stage programs with defined regulatory timelines.
As Cardiol moves toward full enrollment in MAVERIC and progresses CRD-38 toward the clinic, the next 6 to 12 months represent a defined execution period.
Clinical stage biotechnology involves risk, and outcomes depend on trial results and regulatory review. Within the emerging cardiovascular inflammation theme, Cardiol represents a late-stage program with identifiable milestones and human structural heart data already in hand.